123 related articles for article (PubMed ID: 10085870)
1. Factor V Leiden mutation: a nursing perspective.
Page MJ
J Vasc Nurs; 1998 Dec; 16(4):73-7. PubMed ID: 10085870
[TBL] [Abstract][Full Text] [Related]
2. Factor V Leiden mutation and the risks for thromboembolic disease: a clinical perspective.
Price DT; Ridker PM
Ann Intern Med; 1997 Nov; 127(10):895-903. PubMed ID: 9382368
[TBL] [Abstract][Full Text] [Related]
3. Oral contraceptives enhance the risk of clinical manifestation of venous thrombosis at a young age in females homozygous for factor V Leiden.
Rintelen C; Mannhalter C; Ireland H; Lane DA; Knöbl P; Lechner K; Pabinger I
Br J Haematol; 1996 May; 93(2):487-90. PubMed ID: 8639453
[TBL] [Abstract][Full Text] [Related]
4. Factor V Leiden: a review of the literature.
Ament L
J Perinat Neonatal Nurs; 2003; 17(3):190-5. PubMed ID: 12959480
[TBL] [Abstract][Full Text] [Related]
5. Factor V Leiden mutation in pregnancy.
Cohen SM
J Obstet Gynecol Neonatal Nurs; 2004; 33(3):348-53. PubMed ID: 15180198
[TBL] [Abstract][Full Text] [Related]
6. Factor V Leiden mutation and the risk of venous thromboembolism in pregnant women.
Tormene D; Simioni P; Prandoni P; Luni S; Zerbinati P; Sartor D; Franz F; Girolami A
Haematologica; 2001 Dec; 86(12):1305-9. PubMed ID: 11726323
[TBL] [Abstract][Full Text] [Related]
7. Effect of exogenous estrogen on atherothrombotic vascular disease risk related to the presence or absence of the factor V Leiden mutation (resistance to activated protein C).
Glueck CJ; Wang P; Fontaine RN; Tracy T; Sieve-Smith L; Lang JE
Am J Cardiol; 1999 Sep; 84(5):549-54. PubMed ID: 10482153
[TBL] [Abstract][Full Text] [Related]
8. [The frequency of venous thromboembolism in women with Leiden mutation in association with pregnancy and puerperium].
Dulícek P; Malý J; Kalousek I; Beránek M; Pecka M
Ceska Gynekol; 2005 Mar; 70(2):133-8. PubMed ID: 15918268
[TBL] [Abstract][Full Text] [Related]
9. Additional genetic risk factors for venous thromboembolism in carriers of the factor V Leiden mutation.
Tosetto A; Rodeghiero F; Martinelli I; De Stefano V; Missiaglia E; Chiusolo P; Mannucci PM
Br J Haematol; 1998 Dec; 103(3):871-6. PubMed ID: 9858248
[TBL] [Abstract][Full Text] [Related]
10. Selective screening for the Factor V Leiden mutation: is it advisable prior to the prescription of oral contraceptives?
Schambeck CM; Schwender S; Haubitz I; Geisen UE; Grossmann RE; Keller F
Thromb Haemost; 1997 Dec; 78(6):1480-3. PubMed ID: 9423798
[TBL] [Abstract][Full Text] [Related]
11. The incidence of venous thromboembolism in family members of patients with factor V Leiden mutation and venous thrombosis.
Middeldorp S; Henkens CM; Koopman MM; van Pampus EC; Hamulyák K; van der Meer J; Prins MH; Büller HR
Ann Intern Med; 1998 Jan; 128(1):15-20. PubMed ID: 9424976
[TBL] [Abstract][Full Text] [Related]
12. The risk of recurrent venous thromboembolism in heterozygous carriers of factor V Leiden and a first spontaneous venous thromboembolism.
Eichinger S; Weltermann A; Mannhalter C; Minar E; Bialonczyk C; Hirschl M; Schönauer V; Lechner K; Kyrle PA
Arch Intern Med; 2002 Nov; 162(20):2357-60. PubMed ID: 12418950
[TBL] [Abstract][Full Text] [Related]
13. Prevalence and association of the factor V Leiden and prothrombin G20210A in healthy subjects and patients with venous thromboembolism.
Coen D; Zadro R; Honović L; Banfić L; Stavljenić Rukavina A
Croat Med J; 2001 Aug; 42(4):488-92. PubMed ID: 11471205
[TBL] [Abstract][Full Text] [Related]
14. The risk of recurrent venous thromboembolism in patients with and without factor V Leiden.
Eichinger S; Pabinger I; Stümpflen A; Hirschl M; Bialonczyk C; Schneider B; Mannhalter C; Minar E; Lechner K; Kyrle PA
Thromb Haemost; 1997 Apr; 77(4):624-8. PubMed ID: 9134632
[TBL] [Abstract][Full Text] [Related]
15. A prospective study of asymptomatic carriers of the factor V Leiden mutation to determine the incidence of venous thromboembolism.
Middeldorp S; Meinardi JR; Koopman MM; van Pampus EC; Hamulyák K; van Der Meer J; Prins MH; Büller HR
Ann Intern Med; 2001 Sep; 135(5):322-7. PubMed ID: 11529695
[TBL] [Abstract][Full Text] [Related]
16. Combined effect of factor V Leiden and prothrombin 20210A on the risk of venous thromboembolism--pooled analysis of 8 case-control studies including 2310 cases and 3204 controls. Study Group for Pooled-Analysis in Venous Thromboembolism.
Emmerich J; Rosendaal FR; Cattaneo M; Margaglione M; De Stefano V; Cumming T; Arruda V; Hillarp A; Reny JL
Thromb Haemost; 2001 Sep; 86(3):809-16. PubMed ID: 11583312
[TBL] [Abstract][Full Text] [Related]
17. Testing for factor V Leiden in patients with pulmonary or venous thromboembolism: a cost-effectiveness analysis.
Eckman MH; Singh SK; Erban JK; Kao G
Med Decis Making; 2002; 22(2):108-24. PubMed ID: 11958494
[TBL] [Abstract][Full Text] [Related]
18. Factor V Leiden: should we screen oral contraceptive users and pregnant women?
Vandenbroucke JP; van der Meer FJ; Helmerhorst FM; Rosendaal FR
BMJ; 1996 Nov; 313(7065):1127-30. PubMed ID: 8916702
[TBL] [Abstract][Full Text] [Related]
19. Factor V Leiden, hormone replacement therapy, and risk of venous thromboembolic events in women with coronary disease.
Herrington DM; Vittinghoff E; Howard TD; Major DA; Owen J; Reboussin DM; Bowden D; Bittner V; Simon JA; Grady D; Hulley SB
Arterioscler Thromb Vasc Biol; 2002 Jun; 22(6):1012-7. PubMed ID: 12067913
[TBL] [Abstract][Full Text] [Related]
20. Normalized activated protein C ratio itself not associated with increased risk of venous thromboembolism.
Heinemann LA; Assmann A; Spannagl M; Schramm W; Dick A; Kluft C; de Maat MP
Contraception; 1998 Nov; 58(5):321-2. PubMed ID: 9883389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
